The diagnostic and prognostic value of serum human kallikrein-related peptidases 11 in non-small cell lung cancer

Xu, Chunhua; Yu, Zhuang; Yu, Li

doi:10.1007/s13277-014-1674-x

Cited by 9 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentration of tissue proteases, which facilitate cancer cell invasion and metastasis, has been shown to increase in the blood of cancer patients; [1,2] the concentration of protease inhibitors also increases. [3] Beside the diagnostic value of protease concentrations, their activity can potentially influence molecules and cells circulating in the blood.…”

Section: Introductionmentioning

confidence: 99%

Protease Activity and Cell-Free DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients

Тамкович

Bryzgunova

2015

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

Tumor development is generally accompanied by increased protease activity and cell-free DNA (cfDNA) levels in the blood. An immunoassay for protease activity was developed based on the binding of anti-peptide antibodies onto polystyrene plates, followed by incubation with peptides and protein hydrolyzing enzymes. The data obtained demonstrate the peptide CD34-1 composed of uncharged amino acids was the best substrate for the estimation of plasma protease activity in breast cancer patients and healthy donors. Anti-CD34-1 peptide protease activity was shown to correlate with circulating DNA concentrations in cancer patients and healthy subjects (P = 0.001, r = 0.676), demonstrating the role of protease activity in the regulation of cfDNA levels.

show abstract

Section: Introductionmentioning

confidence: 99%

Protease Activity and Cell-Free DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients

Тамкович

Bryzgunova

2015

Journal of Immunoassay and Immunochemistry

View full text Add to dashboard Cite

show abstract

“…While in the LUAD-favorable gene set, genes that were significantly associated with LUAD survival included OR7E47P, MS4A2, RAB44, BMP5, ARHGEF6, KLK11and etc. Among them, KLK11 was found to be a diagnostic and prognostic indicator of NSCLC 31 . This just more confirms the possibility that the LUAD-unfavorable gene set and LUADunfavorable gene set can be used as a prognostic model for LUAD.…”

Section: Discussionmentioning

confidence: 99%

Identification and validation of two LUAD-development characteristic gene sets for diagnosing lung adenocarcinoma and predicting prognosis

Liu

Shao

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose Lung adenocarcinoma (LUAD) is one of the main types of lung cancer, the low rates for early diagnosis and a bad prognosis for advanced stage lead to a higher mortality rate. Therefore, it is of great significance to identify the related genes that promote its development.Patients and methods 512 LUADs from The Cancer Genome Atlas were used to performed differentially expressed gene (DEG) analysis and short-term time-series expression miner to identify the LUAD-development characteristic gene sets. Survival analysis was applied to identified LUAD-unfavorable gene set and LUAD-favorable gene set. Gene set variation analysis (GSVA) was performed to score individual samples against the two gene sets. ROC curve analysis, univariate and multivariate cox regression analysis were used to evaluate the diagnostic and prognostic value of the two GSVA score systems. Two independent data sets from GEO were used for verifying the results. Functional enrichment analysis was used to explore the potential biological functions of LUAD-unfavorable gene set.Results With the development of LUAD, 185 DEGs were gradually up-graduated, including 84 genes associated with survival and classed as LUAD-unfavorable gene set; 237 DEGs were gradually down-graduated, including 39 genes associated with survival and classed as LUAD-favorable gene set. ROC curve analysis and univariate/multivariate Cox proportional hazards analyses indicated both of LUAD-unfavorable GSVA score and LUAD-favorable GSVA score were biomarkers for diagnosing LUAD and independent biomarkers for predicting prognosis. The LUAD-unfavorable genes were involved in multiple cancer-related pathways, such as p53 signaling pathway and cell cycle.ConclusionWe identified and validated two LUAD-development characteristic gene sets that not only have diagnostic value but also prognostic value. It may provide new insight for further research on LUAD.

show abstract

“…They found that patients with NSCLC had lower levels of KLK5, KLK7, KLK8, KLK10, and KLK12, and higher levels of KLK11, KLK13, and KLK14 compared to controls and proposed a multiparametric panel of kallikrein markers for the diagnosis of NSCLC with relatively good accuracy [ 7 ]. Similarly, Xu et al [ 5 ] evaluated the diagnostic and prognostic value of serum human kallikrein–related peptidases 11 level in NSCLC. They collected serum specimens from 138 patients with NSCLC and 40 healthy controls.…”

Section: Discussionmentioning

confidence: 99%

“…They collected serum specimens from 138 patients with NSCLC and 40 healthy controls. They observed that serum human kallikrein–related peptidases 11 levels were significantly higher in NSCLC compared to that in the controls and NSCLC patients with serum high human kallikrein–related peptidases 11 had a longer overall survival and progression-free survival than those with low human kallikrein–related peptidases 11 and concluded that serum human kallikrein–related peptidases 11 might be a useful diagnostic and prognostic test for NSCLC patients [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

“…New biological markers, which can predict patients with higher risk and poor outcome, can be a new therapeutic approach. The potential uses of the markers include aiding early diagnosis, determining prognosis, prospectively predicting response or resistance to specific therapies, and monitoring therapy in patients with advanced disease [ 4 , 5 ]. Kallikreins, a subgroup of the serine protease enzyme family, are expressed in many tissues, including steroid hormone-producing or hormone-dependent tissues such as the prostate, breast, ovary, and testis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?

et al. 2016

View full text Add to dashboard Cite

PurposeInvolvement of human kallikreins (hKs) in human cancers has been reported and several hKs are promising biomarkers of various cancers. The aim of this study was to evaluate the prognostic significance of hK11 expression in patients with non-metastatic non-small cell lung cancer (NSCLC).Materials and MethodsThe study included 44 patients with NSCLC. hK11 expression was determined by immunohistochemical staining.ResultsThe estimation of disease-free and overall survival by Kaplan-Meier was 11 months and 17 months, respectively. The estimation of overall survival by Kaplan-Meier was significantly higher in patients with hK11 strongly positive (2+) than in those with hK11 weakly positive (1+) (20 months vs. 11 months, p=0.032). Although not statistically different, the estimation of disease-free survival by Kaplan-Meier was higher in patients with hK11 strongly positive (2+) than in those with hK11 weakly positive (1+) (12 months vs. 9 months, p=0.113). Multivariate Cox regression analysis showed that the overall survival rates were significantly associated with response to chemoradiotherapy and the degree of staining with hK11.ConclusionThe stronger hK11 expression in NSCLC appears to be associated with better survival rates. hK11 may be a prognostic biomarker of NSCLC.

show abstract

The diagnostic and prognostic value of serum human kallikrein-related peptidases 11 in non-small cell lung cancer

Cited by 9 publications

References 22 publications

Protease Activity and Cell-Free DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients

Protease Activity and Cell-Free DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients

Identification and validation of two LUAD-development characteristic gene sets for diagnosing lung adenocarcinoma and predicting prognosis

Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?

Contact Info

Product

Resources

About